BioWorld

Aug. 27, 2004

View Archived Issues

Eyetech, Pfizer Go Before FDA Panel With Macugen

Eyetech Pharmaceuticals Inc. and partner Pfizer Inc. today are scheduled to present data supporting use of the potential blockbuster Macugen as a treatment for neovascular or wet age-related macular degeneration. (BioWorld Today) Read More

Gilead's Combo Beats Glaxo Pill At 24-Week Study Mark

Read More

Ambit Enters Roche Deal, Garners $21M In Series C

Read More

Centocor's Latest Warning For Remicade Called 'Non-Event'

Read More

Other News To Note

Read More